ASCL1 and neoplasm: In vivo, although reduction of CELSR3 did not impact NEPC tumor growth rate or metastatic potential, we did find that reduction of CELSR3 resulted in a diminution of NEPC markers (e.g., SYP, ASCL1, INSM1, SYP, and CHGA) in vitro and in vivo.